سعر ازيثرومين 250 مجم 6 كبسولات 2023

Azithromin: azithromycin 250 mg capsules, pack of 6; macrolide (azalide) antibacterial. Company: El Nile.

• Acute streptococcal tonsillitis and pharyngitisPopulation: Adults and adolescents (12-17 years) weighing at least 45 kgelectronic Medicines Compendium (eMC, UK)
• Acute bacterial sinusitisPopulation: Adults and adolescents (12-17 years) weighing at least 45 kgelectronic Medicines Compendium (eMC, UK)
• Acute bacterial otitis mediaPopulation: Adults and adolescents (12-17 years) weighing at least 45 kgelectronic Medicines Compendium (eMC, UK)

• Most commonly reported adverse reactions include diarrhoea, headache, vomiting, abdominal pain, nausea and abnormal laboratory values. Other important reactions: anaphylactic reactions, torsades de pointes and arrhythmia including ventricular tachycardia, pseudomembranous colitis, hepatic failure, and severe cutaneous adverse reactions (SJS, TEN, DRESS, AGEP).International label, same formulation · electronic Medicines Compendium (eMC, UK)

• Hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or to any of the excipients.International label, same formulation · electronic Medicines Compendium (eMC, UK)

• Potential for resistance: long-lasting, decreasing plasma and tissue levels after treatment may favour resistance; start only after careful benefit-risk assessment considering local resistance, when preferred regimens are not indicated.International label, same formulation · electronic Medicines Compendium (eMC, UK)
• Rare serious allergic reactions (angioedema, anaphylaxis) and severe cutaneous adverse reactions (SJS, TEN, DRESS, AGEP), which can be life-threatening; symptoms may recur and need prolonged observation. Discontinue if an allergic reaction occurs.International label, same formulation · electronic Medicines Compendium (eMC, UK)
• QT prolongation with risk of arrhythmia and torsades de pointes: use with caution in patients with congenital or documented QT prolongation, those on other QT-prolonging drugs, electrolyte disturbance (hypokalaemia, hypomagnesaemia), clinically relevant bradycardia, arrhythmia or severe cardiac insufficiency, and elderly patients.International label, same formulation · electronic Medicines Compendium (eMC, UK)

• P-glycoprotein substrates (e.g., digoxin, colchicine)Azithromycin inhibits P-gp; co-administration may increase exposure of P-gp substrates. For narrow therapeutic index drugs use caution with clinical and/or therapeutic drug monitoring and dose adjustment as appropriate.electronic Medicines Compendium (eMC, UK)
• QT-prolonging medicines (class IA and III antiarrhythmics, pimozide, citalopram, fluoroquinolones, cisapride, chloroquine, hydroxychloroquine)Use with caution because of additive risk of QT prolongation and ventricular arrhythmia.electronic Medicines Compendium (eMC, UK)
• Statins (e.g., atorvastatin)No pharmacokinetic change in atorvastatin, but post-marketing cases of rhabdomyolysis have been reported with azithromycin and statins; exercise caution.electronic Medicines Compendium (eMC, UK)

• Animal studies showed no evidence of foetal harm. Observational data from more than 7000 exposed pregnancies mostly do not suggest an increased risk of major congenital or cardiovascular malformations; evidence on miscarriage after early-pregnancy exposure is inconclusive. Use during pregnancy only if clinically needed.International label, same formulation · electronic Medicines Compendium (eMC, UK)
• Azithromycin is excreted in human milk to a substantial extent; diarrhoea, mucosal fungal infection and hypersensitivity can occur in breast-fed infants. Decide whether to discontinue breast-feeding or azithromycin considering the benefit to the child and to the woman.International label, same formulation · electronic Medicines Compendium (eMC, UK)

• Azithromycin: Macrolide antibacterial that binds the 23S rRNA of the bacterial 50S ribosomal subunit and inhibits bacterial protein synthesis.